{"title":"ADA 2020：Ertugliflozin显示可显著减少心力衰竭住院治疗。","authors":"Iskandar Idris","doi":"10.1002/doi2.00024","DOIUrl":null,"url":null,"abstract":"<p>The SGLT2 inhibitor, Ertugliflozin was shown to be non-inferior to placebo for reducing cardiovascular events but significantly reduce heart failure hospitalization, according to a trial presented at the American Diabetes Association's 80th Conference.</p>","PeriodicalId":100370,"journal":{"name":"Diabetes, Obesity and Metabolism Now","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/doi2.00024","citationCount":"0","resultStr":"{\"title\":\"ADA 2020: Ertugliflozin shown to significantly reduce heart failure hospitalization.\",\"authors\":\"Iskandar Idris\",\"doi\":\"10.1002/doi2.00024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The SGLT2 inhibitor, Ertugliflozin was shown to be non-inferior to placebo for reducing cardiovascular events but significantly reduce heart failure hospitalization, according to a trial presented at the American Diabetes Association's 80th Conference.</p>\",\"PeriodicalId\":100370,\"journal\":{\"name\":\"Diabetes, Obesity and Metabolism Now\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/doi2.00024\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity and Metabolism Now\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/doi2.00024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity and Metabolism Now","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/doi2.00024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
ADA 2020: Ertugliflozin shown to significantly reduce heart failure hospitalization.
The SGLT2 inhibitor, Ertugliflozin was shown to be non-inferior to placebo for reducing cardiovascular events but significantly reduce heart failure hospitalization, according to a trial presented at the American Diabetes Association's 80th Conference.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
